Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zanubrutinib Plus Rituximab (Zanu -R) as Fixed Duration, Early Intervention Versus Observation for Patients With Indolent Mantle Cell Lymphoma: a Randomised Phase II Clinical Trial

NCT05635162 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT05635162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05635162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zanubrutinib Plus Rituximab (Zanu -R) as Fixed Duration, Early Intervention Versus Observation for Patients With Indolent Mantle Cell Lymphoma: a Randomised Phase II Clinical Trial
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Recruiting
Start date
May 17, 2024
Completion date
October 31, 2028
Enrollment
50 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma